Study wrapper · #289
Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide.
Editor's note
A preclinical efficacy study in a well-established Alzheimer's mouse model (5xFAD). Researchers gave intranasal GHK-Cu (15 mg/kg, three times weekly for three months) to male and female transgenic mice and reported delayed cognitive impairment, fewer amyloid plaques and lower MCP1-related inflammation in the frontal cortex and hippocampus versus controls. The multi-target framing — anti-inflammatory, antioxidant, angiogenic — is biologically coherent with GHK-Cu's proposed mechanisms, and using both sexes strengthens the design. But this is a genetically engineered rodent model that overexpresses human amyloid; such models have repeatedly shown benefits that failed to translate to human Alzheimer's disease. Dose, route and species differ substantially from any human use, and there are no human data on systemic or intranasal GHK-Cu for cognition. These are preclinical findings; human trials are needed before clinical conclusions can be drawn. Treat this as an early mechanistic signal warranting further study, not evidence of benefit in people.
Plain-language abstract
Alzheimer's disease is a brain disorder for which few disease-modifying options exist. GHK-Cu is a naturally occurring peptide that, in its copper-bound form, has anti-inflammatory and antioxidant properties and has been reported to improve thinking in aging mice. Researchers tested whether it could reduce Alzheimer's-like changes in 5xFAD mice — animals genetically engineered to build up amyloid, a hallmark of the disease. Starting at four months of age, male and female mice received GHK-Cu sprayed into the nose (15 mg per kg of body weight) three times a week for three months. Compared with untreated mice, the treated mice showed slower decline on memory and thinking tasks, fewer amyloid plaques, and lower levels of an inflammation marker (MCP1) in memory-related brain regions. The authors say the results justify further studies of GHK-Cu for Alzheimer's. Because this was done in a mouse model that only mimics parts of human Alzheimer's, the findings cannot tell us whether GHK-Cu would help people. No side effects were described in the abstract.